vatalanib (PTK787) / Bayer, Novartis  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
vatalanib (PTK787) / Novartis, Bayer
2004-001605-10: A Phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors GISTs resistant to imatinib mesylate

Ongoing
2
10
Europe
L01XX, PTK787/ZK222584,
ISTITUTO NAZIONALE PER LA CURA TUMORI
Metastatic gastrointestinal stromal tumors GISTs
 
 
2005-005669-12: A dose-finding study of PTK787/ZK 222584 in combination with weekly vinorelbine and trastuzumab as treatment of patients with metastatic breast cancer overexpressing HER-2/neu pre-treated withy at least one line of chemotherapy.

Ongoing
2
18
Europe
PTK787/ZK 222584,
AZIENDA OSPEDALIERA S. FILIPPO NERI
 
 
2006-004824-35: A double-blind, randomized phase II study of once daily versus twice daily PTK787/ZK 222584 treatment in patients with advanced, previously treated metastatic adenocarcinoma of the colon or rectum

 
2
30
Europe
PTK787/ZK 222584, SH T00268C,
Schering AG
advanced, previously treated metastatic adenocarcinoma of the colon or rectum
 
05/07
2004-002420-18: A prospective, non-randomised, non-controlled, open label, multicentre phase II study: PTK 787/ZK222584 in patients with advanced neuroendocrine tumours

Ongoing
2
30
Europe
PTKZK 787, PTKZK 787,
Prof. B. Wiedenmann, Klinik für Gastroenterologie, Charité, Campus Virchow, CHARITE Universitätsmedizin Berlin Campus Virchow-Klinikum
Neuroendocrine Tumour
 
 

Download Options